Skip to main content
Erschienen in: Supportive Care in Cancer 8/2014

01.08.2014 | Review Article

Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review

verfasst von: Floortje Mols, Tonneke Beijers, Gerard Vreugdenhil, Lonneke van de Poll-Franse

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

The objective of this study was to systematically review all available literature concerning chemotherapy-induced peripheral neuropathy (CIPN) and quality of life (QOL) among cancer patients.

Methods

A computerized search of the literature was performed in December 2013. Articles were included if they investigated CIPN and QOL among cancer patients. Twenty-five articles were selected and were subjected to a 13-item quality checklist independently by two investigators.

Results

The methodological quality of the majority of the selected studies was adequate to high. The included studies differed tremendously with respect to study design (19 prospective studies, 5 cross-sectional, 1 both cross-sectional and prospective), patient population (lung, colorectal, ovarian, endometrial, cervical or breast cancer, lymphoma, acute lymphoblastic leukemia, or a mixed population), number of included patients (ranging from 14 to 1643), and ways to assess CIPN (objectively, subjectively, or both). Of the 25 included studies, 11 assessed the association of CIPN on patients’ QOL. While three of these studies did not find an association between CIPN and QOL, the others concluded that more CIPN was associated with a lower QOL.

Implications for cancer survivors

Although the included studies in this systematic review were very diverse, which impedes drawing firm conclusions on this topic, CIPN is likely to have a negative association with QOL. The variety of the studied patient populations and chemotherapeutic agents in the existing studies calls for further studies on this topic. These studies are preferably prospective in nature, include a large number of patients, and assess QOL and CIPN with validated questionnaires.
Literatur
1.
Zurück zum Zitat Gutiérrez-Gutiérrez G et al (2010) Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol 12(2):81–91PubMedCrossRef Gutiérrez-Gutiérrez G et al (2010) Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol 12(2):81–91PubMedCrossRef
2.
Zurück zum Zitat Kannarkat G, Lasher E, Schiff D (2007) Neurologic complications of chemotherapy agents. Curr Opin Neurol 20(6):719–725PubMed Kannarkat G, Lasher E, Schiff D (2007) Neurologic complications of chemotherapy agents. Curr Opin Neurol 20(6):719–725PubMed
3.
Zurück zum Zitat Sukel MP et al (2008) Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990–2006 in the southeastern Netherlands. Eur J Cancer 44(13):1846–1854PubMedCrossRef Sukel MP et al (2008) Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990–2006 in the southeastern Netherlands. Eur J Cancer 44(13):1846–1854PubMedCrossRef
4.
Zurück zum Zitat Dassen AE et al (2010) Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer 46(6):1101–1110PubMedCrossRef Dassen AE et al (2010) Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer 46(6):1101–1110PubMedCrossRef
5.
Zurück zum Zitat Elferink MA et al (2010) Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989–2006. Eur J Cancer 46(8):1421–1429PubMedCrossRef Elferink MA et al (2010) Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989–2006. Eur J Cancer 46(8):1421–1429PubMedCrossRef
6.
Zurück zum Zitat van Steenbergen LN et al (2012) Increased adjuvant treatment and improved survival in elderly stage III colon cancer patients in The Netherlands. Ann Oncol 23(11):2805–2811PubMedCrossRef van Steenbergen LN et al (2012) Increased adjuvant treatment and improved survival in elderly stage III colon cancer patients in The Netherlands. Ann Oncol 23(11):2805–2811PubMedCrossRef
7.
Zurück zum Zitat Beijers AJ, Jongen JL, Vreugdenhil G (2012) Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med 70(1):18–25PubMed Beijers AJ, Jongen JL, Vreugdenhil G (2012) Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med 70(1):18–25PubMed
8.
Zurück zum Zitat Beijers AJM, Mols F, Vreugdenhil G (2014) A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer. doi:10.1007/s00520-014-2242-z Beijers AJM, Mols F, Vreugdenhil G (2014) A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer. doi:10.​1007/​s00520-014-2242-z
9.
Zurück zum Zitat Markman M (1996) Chemotherapy-associated neurotoxicity: an important side effect-impacting on quality, rather than quantity, of life. J Cancer Res Clin Oncol 122(9):511–512PubMedCrossRef Markman M (1996) Chemotherapy-associated neurotoxicity: an important side effect-impacting on quality, rather than quantity, of life. J Cancer Res Clin Oncol 122(9):511–512PubMedCrossRef
10.
Zurück zum Zitat Tofthagen C (2010) Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med 13(11):1389–1391PubMedCrossRef Tofthagen C (2010) Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med 13(11):1389–1391PubMedCrossRef
11.
Zurück zum Zitat Bakitas MA (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56(5):323–331PubMedCrossRef Bakitas MA (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56(5):323–331PubMedCrossRef
12.
Zurück zum Zitat Bezjak A et al (2004) Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol 22(22):4595–4603PubMedCrossRef Bezjak A et al (2004) Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol 22(22):4595–4603PubMedCrossRef
13.
Zurück zum Zitat Brundage M et al (2012) Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial. Ann Oncol Off J Eur Soc Med Oncol / ESMO 23(8):2020–2027CrossRef Brundage M et al (2012) Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial. Ann Oncol Off J Eur Soc Med Oncol / ESMO 23(8):2020–2027CrossRef
14.
Zurück zum Zitat Bruner DW et al (2007) Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. Qual Life Res Int J Qual Life Asp Treat Care and Rehab 16(1):89–100CrossRef Bruner DW et al (2007) Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. Qual Life Res Int J Qual Life Asp Treat Care and Rehab 16(1):89–100CrossRef
15.
Zurück zum Zitat Butler L et al (2004) Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol Off J Am Soc Clin Oncol 22(12):2461–2468CrossRef Butler L et al (2004) Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol Off J Am Soc Clin Oncol 22(12):2461–2468CrossRef
16.
Zurück zum Zitat Calhoun EA et al (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13(6):741–748PubMedCrossRef Calhoun EA et al (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13(6):741–748PubMedCrossRef
17.
Zurück zum Zitat Cavaletti G et al (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24(2):454–462PubMedCentralPubMedCrossRef Cavaletti G et al (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24(2):454–462PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Cella D et al (2003) Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane). Cancer 98(4):822–831PubMedCrossRef Cella D et al (2003) Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane). Cancer 98(4):822–831PubMedCrossRef
19.
Zurück zum Zitat Cella D et al (2010) Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 119(3):531–537PubMedCrossRef Cella D et al (2010) Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 119(3):531–537PubMedCrossRef
20.
Zurück zum Zitat Driessen CM et al (2012) Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer 20(4):877–881PubMedCentralPubMedCrossRef Driessen CM et al (2012) Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer 20(4):877–881PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Griffith KA et al (2014) Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations. Support Care Cancer 22(5):1161–1169PubMedCrossRef Griffith KA et al (2014) Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations. Support Care Cancer 22(5):1161–1169PubMedCrossRef
22.
Zurück zum Zitat Hershman DL et al (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767–774PubMedCrossRef Hershman DL et al (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767–774PubMedCrossRef
23.
Zurück zum Zitat Hilpert F et al (2005) Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 13(10):797–805 Hilpert F et al (2005) Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 13(10):797–805
24.
Zurück zum Zitat Kautio AL et al (2008) Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manag 35(1):31–39CrossRef Kautio AL et al (2008) Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manag 35(1):31–39CrossRef
25.
Zurück zum Zitat Kim BJ et al (2010) Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Qual Life Res 19(8):1097–1103PubMedCrossRef Kim BJ et al (2010) Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Qual Life Res 19(8):1097–1103PubMedCrossRef
26.
Zurück zum Zitat Lee SM et al (2009) Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(31):5248–5254CrossRef Lee SM et al (2009) Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(31):5248–5254CrossRef
27.
Zurück zum Zitat Mols F et al (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. doi:10.1200/JCO.2013.49.1514 PubMed Mols F et al (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. doi:10.​1200/​JCO.​2013.​49.​1514 PubMed
28.
Zurück zum Zitat Morita S et al (2003) Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model. Jpn J Clin Oncol 33(9):470–476PubMedCrossRef Morita S et al (2003) Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model. Jpn J Clin Oncol 33(9):470–476PubMedCrossRef
29.
Zurück zum Zitat Ostchega Y, Donohue M, Fox N (1988) High-dose cisplatin-related peripheral neuropathy. Cancer Nurs 11(1):23–32PubMedCrossRef Ostchega Y, Donohue M, Fox N (1988) High-dose cisplatin-related peripheral neuropathy. Cancer Nurs 11(1):23–32PubMedCrossRef
30.
Zurück zum Zitat Ramchandren S et al (2009) Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst: JPNS 14(3):184–189PubMedCrossRef Ramchandren S et al (2009) Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst: JPNS 14(3):184–189PubMedCrossRef
31.
Zurück zum Zitat Richter R et al (2012) Health-related quality of life during sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: a multicenter phase II study of the North Eastern German Society of Gynecological Oncology. Anticancer Res 32(9):3969–3976PubMed Richter R et al (2012) Health-related quality of life during sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: a multicenter phase II study of the North Eastern German Society of Gynecological Oncology. Anticancer Res 32(9):3969–3976PubMed
32.
Zurück zum Zitat Shimozuma K et al (2012) Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 20(12):3355–3364 Shimozuma K et al (2012) Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 20(12):3355–3364
33.
Zurück zum Zitat Smith EM et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA J Am Med Assoc 309(13):1359–1367CrossRef Smith EM et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA J Am Med Assoc 309(13):1359–1367CrossRef
34.
Zurück zum Zitat Sorbe B et al (2012) A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation. Int J Oncol 40(3):773–781PubMed Sorbe B et al (2012) A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation. Int J Oncol 40(3):773–781PubMed
35.
Zurück zum Zitat Tofthagen C (2010) Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 14(3):E22–E28PubMedCrossRef Tofthagen C (2010) Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 14(3):E22–E28PubMedCrossRef
36.
Zurück zum Zitat Wenzel LB et al (2007) Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol Off J Am Soc Clin Oncol 25(4):437–443CrossRef Wenzel LB et al (2007) Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol Off J Am Soc Clin Oncol 25(4):437–443CrossRef
37.
Zurück zum Zitat Mols F et al (2005) Quality of life among long-term breast cancer survivors: a systematic review. Eur J Cancer 41(17):2613–2619PubMedCrossRef Mols F et al (2005) Quality of life among long-term breast cancer survivors: a systematic review. Eur J Cancer 41(17):2613–2619PubMedCrossRef
38.
Zurück zum Zitat Den Oudsten BL, Van Heck GL, De Vries J (2007) Quality of life and related concepts in Parkinson’s disease: a systematic review. Mov Disord 22(11):1528–1537CrossRef Den Oudsten BL, Van Heck GL, De Vries J (2007) Quality of life and related concepts in Parkinson’s disease: a systematic review. Mov Disord 22(11):1528–1537CrossRef
39.
Zurück zum Zitat Pachman DR et al (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90(3):377–387PubMedCrossRef Pachman DR et al (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90(3):377–387PubMedCrossRef
Metadaten
Titel
Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review
verfasst von
Floortje Mols
Tonneke Beijers
Gerard Vreugdenhil
Lonneke van de Poll-Franse
Publikationsdatum
01.08.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2255-7

Weitere Artikel der Ausgabe 8/2014

Supportive Care in Cancer 8/2014 Zur Ausgabe

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.